BACKGROUND: As many as 20 million people are living with Trypanosoma cruzi infection in Latin American, yet few receive any treatment. The major limitation in developing and evaluating potential new drugs for their efficacy is the lack of reliable tests to assess parasite burden and elimination. METHODS:Adults volunteers with chronic T. cruzi infection were evaluated clinically and stratified according to the Kuschnir classification. Individuals with group 0 and group 1 clinical status were treated with benznidazole (5 mg/kg per day for 30 days). The changes in T. cruzi-specific T cell and antibody responses, as well as in clinical status, were measured periodically over the 3-5-year follow-up period and were compared with pretreatment conditions and with values in an untreated control group. RESULTS: The frequency of peripheral interferon (IFN)-gamma-producing T cells specific for T. cruzi declined as early as 12 months after benznidazole treatment and subsequently became undetectable in a substantial proportion of treated subjects. In addition, decreases in antibody responses to a pool of recombinant T. cruzi proteins also decreased in many of these same subjects. The shift to negative IFN-gamma T cell responses was highly associated with an early increase in IFN-gamma-producing T cells with phenotypic features of effector/effector memory cells in a subset of subjects. Benznidazole treatment also resulted in an increase in naive and early differentiated memory-like CD8(+) T cells in a majority of subjects. CONCLUSIONS:Benznidazole treatment during chronic Chagas disease has a substantial impact on parasite-specific immune response that is likely indicative of treatment efficacy and cure.
RCT Entities:
BACKGROUND: As many as 20 million people are living with Trypanosoma cruzi infection in Latin American, yet few receive any treatment. The major limitation in developing and evaluating potential new drugs for their efficacy is the lack of reliable tests to assess parasite burden and elimination. METHODS: Adults volunteers with chronic T. cruzi infection were evaluated clinically and stratified according to the Kuschnir classification. Individuals with group 0 and group 1 clinical status were treated with benznidazole (5 mg/kg per day for 30 days). The changes in T. cruzi-specific T cell and antibody responses, as well as in clinical status, were measured periodically over the 3-5-year follow-up period and were compared with pretreatment conditions and with values in an untreated control group. RESULTS: The frequency of peripheral interferon (IFN)-gamma-producing T cells specific for T. cruzi declined as early as 12 months after benznidazole treatment and subsequently became undetectable in a substantial proportion of treated subjects. In addition, decreases in antibody responses to a pool of recombinant T. cruzi proteins also decreased in many of these same subjects. The shift to negative IFN-gamma T cell responses was highly associated with an early increase in IFN-gamma-producing T cells with phenotypic features of effector/effector memory cells in a subset of subjects. Benznidazole treatment also resulted in an increase in naive and early differentiated memory-like CD8(+) T cells in a majority of subjects. CONCLUSIONS:Benznidazole treatment during chronic Chagas disease has a substantial impact on parasite-specific immune response that is likely indicative of treatment efficacy and cure.
Authors: C Britto; C Silveira; M A Cardoso; P Marques; A Luquetti; V Macêdo; O Fernandes Journal: Mem Inst Oswaldo Cruz Date: 2001-08 Impact factor: 2.743
Authors: P A Goepfert; A Bansal; B H Edwards; G D Ritter; I Tellez; S A McPherson; S Sabbaj; M J Mulligan Journal: J Virol Date: 2000-11 Impact factor: 5.103
Authors: N H Gruener; F Lechner; M C Jung; H Diepolder; T Gerlach; G Lauer; B Walker; J Sullivan; R Phillips; G R Pape; P Klenerman Journal: J Virol Date: 2001-06 Impact factor: 5.103
Authors: D Fabbro De Suasnábar; E Arias; M Streiger; M Piacenza; M Ingaramo; M Del Barco; N Amicone Journal: Rev Inst Med Trop Sao Paulo Date: 2000 Mar-Apr Impact factor: 1.846
Authors: L Lauria-Pires; M S Braga; A C Vexenat; N Nitz; A Simões-Barbosa; D L Tinoco; A R Teixeira Journal: Am J Trop Med Hyg Date: 2000 Sep-Oct Impact factor: 2.345
Authors: Susana A Laucella; Miriam Postan; Diana Martin; Bolyn Hubby Fralish; Maria C Albareda; Maria G Alvarez; Bruno Lococo; Gustavo Barbieri; Rodolfo J Viotti; Rick L Tarleton Journal: J Infect Dis Date: 2004-02-17 Impact factor: 5.226
Authors: Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi Journal: Infect Immun Date: 2018-03-22 Impact factor: 3.441
Authors: Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz Journal: Clin Microbiol Rev Date: 2011-07 Impact factor: 26.132
Authors: María Cecilia Albareda; Gabriela Carina Olivera; Ana María De Rissio; Miriam Postan Journal: Am J Trop Med Hyg Date: 2010-05 Impact factor: 2.345
Authors: Christopher S Eickhoff; Daniel Van Aartsen; Frances E Terry; Sheba K Meymandi; Mahmoud M Traina; Salvador Hernandez; William D Martin; Leonard Moise; Annie S De Groot; Daniel F Hoft Journal: Hum Vaccin Immunother Date: 2015-06-24 Impact factor: 3.452
Authors: Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi Journal: Trends Parasitol Date: 2019-10-10
Authors: Joseli Lannes-Vieira; Tania C de Araújo-Jorge; Maria de Nazaré Correia Soeiro; Paulo Gadelha; Rodrigo Corrêa-Oliveira Journal: PLoS Negl Trop Dis Date: 2010-06-29
Authors: Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez; Bin Zhan; Michael J Heffernan; Kathryn Jones; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Bruce Y Lee; Kristina M Bacon; Bernhard Fleischer; B T Slingsby; Miguel Betancourt Cravioto; Roberto Tapia-Conyer Journal: Expert Rev Vaccines Date: 2012-09 Impact factor: 5.217